AbbVie Inc. (ABBV) Financials
PeriodQ2 FY2026
Published
AbbVie reported $16.99 billion in net revenues for Q2 FY2026, the quarter ended June 30, 2026, up 10.2% from a year earlier, and net earnings attributable to AbbVie of $3.61 billion, up 285.2%. Diluted earnings per share were $2.03 against $0.52 a year earlier, a leap well beyond the underlying operating gain: operating earnings of $6.43 billion were up 31.4%, and the rest of the increase came from a much smaller charge for changes in the fair value of contingent consideration liabilities and a far lower effective tax rate than a year ago. The growth is concentrated in immunology: Skyrizi alone brought in $5.50 billion, up 24.5%, while Humira kept losing ground to biosimilars.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $16,990,000,000 | up 10.2% |
| Net income | $3,613,000,000 | up 285.2% |
| Diluted EPS | $2.03 | up 290.4% |
| Operating earnings | $6,432,000,000 | up 31.4% |
| Skyrizi revenue | $5,505,000,000 | up 24.5% |
Company details
| Name | AbbVie Inc. |
|---|---|
| Ticker | ABBV |
| CIK | 0001551152 |
| Exchange | NYSE |
| State | Illinois |
| Incorporation | Delaware |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 10-Q, accession 0001551152-26-000026 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 10-Q around 2026-11-03 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · AbbVie Q2 FY2026
How much revenue did AbbVie report in Q2 FY2026?
AbbVie reported $16.99 billion in net revenues for Q2 FY2026, the quarter ended June 30, 2026. That is up 10.2% from $15.42 billion in the same quarter a year earlier.
What was AbbVie's earnings per share in Q2 FY2026?
AbbVie reported diluted earnings per share of $2.03 for Q2 FY2026, the quarter ended June 30, 2026, against $0.52 in the same quarter a year earlier. Net earnings attributable to AbbVie were $3.61 billion, up 285.2%.
Why did AbbVie's profit rise so much in Q2 FY2026?
AbbVie's operating earnings were $6.43 billion in Q2 FY2026, up 31.4%, while net earnings attributable to AbbVie rose much faster, to $3.61 billion from $938 million. The difference is below the operating line: the quarter carried a much smaller charge for changes in the fair value of contingent consideration liabilities and a far lower effective tax rate than a year earlier.
How much did Skyrizi sell in Q2 FY2026?
Skyrizi generated $5.50 billion of net revenues for AbbVie in Q2 FY2026, the quarter ended June 30, 2026, up 24.5% from $4.42 billion a year earlier. It is AbbVie's largest product and the main driver of the company's growth.
Where can I get AbbVie Inc. (ABBV) financial data in machine-readable form?
Ticker Scout publishes AbbVie Inc.'s financial statements as JSON at https://tickerscout.ai/abbv/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/abbv/narrative.md and https://tickerscout.ai/abbv/events.md. AbbVie Inc.'s SEC CIK is 0001551152. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does AbbVie Inc. (ABBV) next file with the SEC?
AbbVie Inc. (ABBV) is expected to file its next Form 10-Q with the SEC on or around November 3, 2026. That date is a projection rather than a company-announced date: it is derived from AbbVie Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0001551152-26-000026.
Related companies
How this page was built
This page was built from AbbVie Inc.'s own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names four such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.